Business
Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024
SHELTON, Conn., March 14, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the
About this update from Intensity Therapeutics, Inc.
[{"type":"text","content":"SHELTON, Conn., March 14, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces that Lewis H. Bender, Founder, President and Chief Executive Officer, will participate in a fireside chat with Roth Managing Director and Senior Analyst, Jonathan Aschoff, Ph.D. at the 36th Annual Roth Conference in Orange County, CA on Tuesday, March 19, at 12:30PM PDT at the Ritz Carlton in Laguana Nigel, CA in the Healthcare Suite 2022.\n\n \n \n \n \n \n \n\n \nA live webcast of the presentation will be available on the \"Events\" section of Intensity's website at: HTTP://wsw.com/webcast/roth48\nAn archived replay will be available on the company's website for a period of 90 days after the conference.\nMr. Bender will be available for one-on-one meetings during the conference. To schedule a one-on-one meeting, please contact your Roth representative or Justin Kulik at [email protected].\nAbout Intensity TherapeuticsIntensity Therapeutics is a late-stage clinical biotechnology company that applies novel engineered chemistry to turn \"cold\" tumors \"hot\" by enabling its aqueous cytotoxic-containing drug product, INT230-6, to mix and saturate the dense, high-fat pressurized environment of the tumor. As a result of the saturation, Intensity's clinical trials have demonstrated the ability of INT230-6 to kill tumors and elicit an adaptive immune response within days of injection, representing a novel approach to cancer cell death that holds the potential to shift the treatment paradigm and turn many deadly cancers into chronic diseases. INT230-6 has completed enrollment of over 200 patients in a Phase 1/2 dose escalation trial (NCT03058289) and Phase 2 randomized control clinical trial in breast cancer (the INVINCIBLE-2 study) (NCT04781725). The Company is initiating a Phase 3 trial in soft tissue sarcoma (the INVINCIBLE3 study) (NCT06263231), testing INT230-6 as second or third line monotherapy compared to the standard of care with overall survival as an endpoint. The Company is also planning a Phase 2/3 program in presurgical triple negative breast cancer testing INT230-6 in combination with standard of ca...